$15.62
1.63% yesterday
Nasdaq, May 28, 09:47 pm CET
ISIN
US04280A1007
Symbol
ARWR

Arrowhead Pharmaceuticals, Inc. Stock price

$15.56
+2.04 15.09% 1M
-10.59 40.50% 6M
-3.24 17.23% YTD
-8.36 34.95% 1Y
-18.64 54.50% 3Y
-17.53 52.98% 5Y
+9.31 148.96% 10Y
Nasdaq, Closing price Wed, May 28 2025
+0.19 1.24%
ISIN
US04280A1007
Symbol
ARWR
Sector
Industry

Key metrics

Market capitalization $2.12b
Enterprise Value $1.30b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 135.54
EV/Sales (TTM) EV/Sales 2.39
P/S ratio (TTM) P/S ratio 3.89
P/B ratio (TTM) P/B ratio 3.11
Revenue growth (TTM) Revenue growth 1,437.97%
Revenue (TTM) Revenue $545.21m
EBIT (operating result TTM) EBIT $-118.55m
Free Cash Flow (TTM) Free Cash Flow $9.60m
Cash position $1.10b
EPS (TTM) EPS $-1.07
P/E forward 40.24
P/S forward 2.95
EV/Sales forward 1.81
Short interest 12.74%
Show more

Is Arrowhead Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,808 stocks worldwide.

Arrowhead Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:

11x Buy
69%
5x Hold
31%

Analyst Opinions

16 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:

Buy
69%
Hold
31%

Financial data from Arrowhead Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
545 545
1,438% 1,438%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 116 116
8% 8%
21%
- Research and Development Expense 526 526
37% 37%
97%
-97 -97
79% 79%
-18%
- Depreciation and Amortization 21 21
32% 32%
4%
EBIT (Operating Income) EBIT -119 -119
75% 75%
-22%
Net Profit -144 -144
69% 69%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about Arrowhead Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arrowhead Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
16 days ago
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Vincent Anzalone - Vice President of Investor Relations for Arrowhead Christopher Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP & Head of Global Cardio/Metabolic Franchise James Hamilton - Chief Discovery & Translational Medicin...
Neutral
Business Wire
16 days ago
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call today, May 12, 2025, at 4:30 p.m. ET to discuss the results. “Arrowhead is in a strong and stable position as a business, and we have made meaningful progress towards our lo...
Neutral
Business Wire
21 days ago
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: BofA Securities 2025 Health Care Conference – May 13-15, 2025 Type: Fireside Chat Presentation Date/Time: May 14, 2025, 11:20 a.m. PDT 2025 RBC Capital Markets Global Healthcare – May 20-21, 2025 Type: Fireside...
More Arrowhead Pharmaceuticals, Inc. News

Company Profile

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Head office United States
CEO Christopher Anzalone
Employees 609
Founded 1989
Website arrowheadpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today